Semaglutide Helps Dialysis Patients Lose Enough Weight to Qualify for Kidney Transplant | Research

The takeaway

Semaglutide produced significant weight loss in 13 obese dialysis patients over 12 weeks, with three patients subsequently reconsidering transplant listing — demonstrating safety and efficacy in this high-risk population.

3 patients reconsidered for transplant
After semaglutide-induced weight loss in obese dialysis patients previously excluded from transplant listing

What the researchers found

Semaglutide achieved significant weight and BMI reduction in obese dialysis patients (mean 4.6 kg in 12 weeks), with an acceptable safety profile, and three patients were able to reconsider transplant listing.

Why it matters

Kidney transplantation dramatically improves survival and quality of life compared to dialysis, but obesity barriers prevent many patients from even being listed. Semaglutide could serve as a bridge therapy, helping patients lose enough weight to access transplantation.

The numbers in context

13 patients; 12-week prospective open-label trial; all on dialysis with BMI above transplant thresholds.

How the study worked

Prospective, 12-week, open-label, observational study of 13 patients with BMI ≥30 undergoing dialysis, treated with weekly subcutaneous semaglutide titrated from 0.25 mg to 1 mg. Primary endpoint: weight/BMI change by repeated measures ANOVA.

Who was studied

Dialysis patients with obesity preventing kidney transplant eligibility

What this study cannot tell us

Very small sample (n=13). Open-label without control group. Short 12-week treatment period. Two deaths (unrelated) in a high-risk population. Long-term safety in dialysis not established. No pharmacokinetic data specific to dialysis clearance.

How to read the evidence

Preliminary evidence — small prospective open-label study without control group. Important safety signal in an understudied population, but requires larger studies for definitive conclusions.

When this study was published

Published in 2024. Among the first prospective studies of semaglutide in dialysis patients.

The bigger picture

This is among the first studies of GLP-1RAs in dialysis patients — a population typically excluded from clinical trials. Demonstrating safety in this high-risk group opens the door to using weight loss medications as a pathway to transplant eligibility, potentially transforming outcomes for thousands of patients.

Questions still open

Is semaglutide clearance affected by dialysis, requiring dose adjustment?
Can longer treatment courses achieve transplant-eligible BMI in more patients?
Should GLP-1RAs be routinely offered to obese transplant candidates on dialysis?

Common questions

Can people on dialysis take weight loss drugs like semaglutide?

This study suggests yes — semaglutide was safe and effective in 13 patients on dialysis, with side effects similar to the general population. This is important because dialysis patients are usually excluded from weight loss drug studies, leaving doctors with little guidance.

Why would weight loss matter for dialysis patients?

Many kidney transplant centers have weight limits — patients above a certain BMI can't be listed for a transplant. Since transplant dramatically improves survival compared to staying on dialysis, losing weight to qualify can be life-changing. In this study, three patients lost enough weight to reconsider transplant listing.

Read the original research

Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.

Diabetes, obesity & metabolism, 26(12), 5931-5941

View on PubMed ↗Publisher’s paper ↗

Citation

Vanek, Lenka; Kurnikowski, Amelie; Krenn, Simon; Mussnig, Sebastian; Hecking, Manfred. (2024). Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study.. Diabetes, obesity & metabolism, 26(12), 5931-5941. https://doi.org/10.1111/dom.15967